

## Publications / Veröffentlichungen

Döhner H, Schlenk R, Fischer J Th, del Valle F, Pezzutto A, Pfreundschuh M, Weber W, **Distelrath A**, Bürger M, Haas R, Fischer K, Hunstein W.  
Stratification of Postremission Therapy in Adult Acute Myeloid Leukemia According to the Karyotype.  
Preliminary Results of a Multicenter Treatment Trial (AML HD93)  
Annals of Hematology, Suppl. II to Vol. 70 # 160 (1995)

Döhner H, Schlenk R, Fischer J Th, del Valle F, Pezotto A, **Distelrath A**, Hartmann F, Weber W, Bürger H, Göckel F, Haas R, Fischer K, Hunstein W.  
Stratification of Postremission Therapy in Adult Acute Myeloid Leukemia According to the Karyotype.  
Preliminary Results of a Multicenter Treatment Trial (AML HD93)  
Onkologie Suppl. 2 zu Band 18 Oktober 1995 #38

Schlenk R, Döhner H, Pförsisch M, **Distelrath A**, Fischer J Th, Bürger H, Fischer K, Haas R, Hunstein W.  
Mobilization of Peripheral Blood Progenitor Cells in Patients with Acute Myeloid Leukemia Following Intensive Induction Chemotherapy and Consolidation with High-Dose Cytarabine/Mitoxantrone + G-CSF.  
Onkologie Suppl. 2 zu Band 18 Oktober 1995 #570

Klinker H, Schwarzkopf A, Junger O, Kühnlein L, Langmann P, **Distelrath A**.  
Prävention von Aspergillose-Erkrankungen im Rahmen von Baumaßnahmen bei laufendem Klinikbetrieb.  
Immunität und Infektion, Suppl. 1/95, p. 94 (1995)

Ranze O, **Distelrath A**, Hellinger A, Arps H, Höffkes H-G, Kaelble T.  
Intensified ELDP (etoposide, liposomal doxorubicin, cisplatinum) chemotherapy combined with mitotane in a patient with advanced and relapsed metastatic non-functional adrenal carcinoma.  
Onkologie 2005; 28: #876 (Abstract)

Ranze O, Hofmann E, **Distelrath A**, Höffkes H-G.,  
Renal cell cancer presenting with leptomeningeal carcinomatosis responding to sorafenib.  
Onkologie 2007; 30: 450-451 (Kasuistik)

Ranze O, Höffkes H-G, Feldmann H-J, **Distelrath A**, Fassbinder W, Greim C-A, Meissel R.  
Interdisziplinäres Fachkonzept für die palliativmedizinische Versorgung onkologischer Patienten durch das Palliativzentrum Osthessen der Klinikum Fulda gAG.  
3. Fachtagung „Palliative Versorgung und hospizliche Begleitung in Hessen“  
31.01.2007 Bad Nauheim (Poster)

Susanne Schnittger,<sup>1</sup> Ulrike Bacher,<sup>2</sup> Claudia Haferlach,<sup>1</sup> Dietrich Beelen,<sup>3</sup> Peter Bojko,<sup>4</sup> Dieter Bürkle,<sup>5</sup> Robert Dengler,<sup>6</sup> **Andrea Distelrath**,<sup>7</sup> Michael Eckart,<sup>8</sup> Robert Eckert,<sup>9</sup> Stefan Fries,<sup>10</sup> Jan Knoblich,<sup>11</sup> Georg Köchling,<sup>12</sup> Hans-Peter Laubenstein,<sup>13</sup> Petro Petrides,<sup>14</sup> Manfred Planker,<sup>15</sup> Rudolf Pihusch,<sup>16</sup> Rudolf Weide,<sup>17</sup> Wolfgang Kern,<sup>1</sup> and Torsten Haferlach<sup>1</sup>  
Characterization of 35 new cases with four different *MPLW515* mutations and essential thrombocytosis or primary myelofibrosis  
Haematologica. 2009 January; 94(1): 141–144.  
Published online 2008 November 23. doi: 10.3324/haematol.13224.

Members of the German-Austrian Study Group AMLSG.

Insertion of FLT3 Internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome.

Blood, Kayser et al. Vol. 114, Issue 12, p 2386-2392, September 17, 2009

Kaufmann M, Maas N, Costa S d, Schneeweiß A, Loibl S, Sütterlin M W, Schrader I, Gerber B, Bauer W, Wiest W, Tome O, **Distelrath A**, Hagen V, Schreier J, Ruckhäberle E, Metha K, von Minckwitz G.

First line therapy with moderate dose Capecitabine in metastatic Breast Cancer ist safe and effective – Results of the MONICA Trial

European Journal of Cancer ( 2010 ) doi:10.1016/j.ejca.2010.07.009

Co Autor **Distelrath A**,

Erste Publikation zur Post-Marketing-Surveillance-Studie über Noxafil:

Posaconazole in Invasive Mycoses at Daily Medical Course

An On-Line Based, Prospective, Observational Survey – Safety and Tolerability

Original Article prepared for JAC, 2010

Frank O., Mügge L.-O., Scheid C., Schäfer E., Lück A., Scheidegger C., **Distelrath A.**, Plewe D., Gausch G., Bruhn P., Korsten S., Maywald O., Sauer U., Söling U., Heits F., Blumenstengel K., Lakner V., Lerchenmüller C., Ritter U., Hochhaus A.

Increasing the dose of Imatinib ( IM ) is well tolerated and leads to clinical improvement in a significant number of patients ( pts ) with Chronic Myeloid Leukemia ( CML ) – first data of the observation DOSING study.

P507 DGHO 2010

**Andrea Distelrath**, Barbara Scheffler, Melanie Laszczyk

Pilot-Erfahrungen zur Therapie und Prophylaxe von Hautveränderungen unter Chemo- bzw.

Radiochemotherapie mit Betulin-Emulsionen

Zeitschrift für Phytotherapie 2010; 31: 179-184

Gebhard, S., **Distelrath, A.**, Grothe, W., Höffkes, H.-G.

Combined chemotherapy of Rituximab, Fludarabine and Cyclophosphamid (R-FC) is superior in younger patients with B-CLL with respect to molecular remission rates

P818, DGHO Berlin, 2010

Schneeweiss A., Förster F., Hollburg W., Tesch H., Klare P., Wülfing P., **Distelrath A.**, Schumacher C., Steffens C.-C., Schubert R., Widing A., Kasper C., Schmidt M.

First-line Bevacizumab combined with Paclitaxel in triple-negative locally recurrent/metastatic Breast Cancer: subpopulation analysis of 115 patients treated in routine oncology practice in Germany

P2-16-12 SABCS 2010 und #78311 ASCO 2011 und #5.073 EMCC 2011

Dengler J., Coutre P., Stegelmann F., Scheid C., Weide R., Illmer T., Sauer A., Walter M., Schneider-Kappus W., Kröger M., **Distelrath A.**, Stier G., Stern S., Schlegel F., Meincke M., Frank o., Ottmann O.G.

Nilotinib in routine clinical management of CML patients failing prior therapy: Update of the German TARGET study

P886 DGHO 2011-11-24

Möhler M., Kanzler S., Schimanski C.C., Wörns M.A., Denzer U., Kolligs F., Ebert M., **Distelrath A.**, Zeuzem S., Lammert F., Geissler M., Lohse A., Dollinger M., Lindig U., Dürr M., Lubomierski N., Kabisch M., Schadmand-Fischer S., Galle P.R. AIO  
A randomized, double-blind, multicenter phase II AIO trial with Gemcitabine plus Sorafenib versus Gemcitabine plus placebo in patients with chemo-naïve advanced or metastatic biliary tract cancer: first safety and efficacy data  
# 80719 ASCO 2011 und V736 DGHO 2011-11-24

#### **SABCS 2014: Advanced Disease Treatment**

**4EVER - Final analysis of the phase IIIb, multi-center, open label study for postmenopausal women with estrogen receptor positive locally advanced or metastatic breast cancer (BC) treated with everolimus (EVE) in combination with exemestane (EXE).**

H Tesch, O Stoetzer, T Decker, C Kurbacher, R Neumeister, F. Marme', A Schneeweiss, C Mundhenke, **A Distelrath**, P Fasching, M Lux, D Lueftner, P Hadji, W Janni, M Muth, J Kreuzeder, D Wallwiener

#### **SABCS 2014: PROGNOSTIC AND PREDICTIVE FACTORS**

**4EVER: mTOR inhibition has a major clinical impact on bone health in postmenopausal women with hormone receptor positive (HR+) advanced breast cancer (ABC) treated with everolimus (EVE) in combination with exemestane (EXE)**

P Hadji, H Tesch, O Stoetzer, T Decker, C Kurbacher, R Neumeister, F Marme', A Schneeweiss, C Mundhenke, **A Distelrath**, P Fasching, M Lux, D Lueftner, W Janni, M Muth, J Kreuzeder, E Grischke

#### **ASCO 2016 Abstract**

**Subcutaneous trastuzumab therapy for HER2-positive early breast cancer in the routine clinical practice – 1st interim analysis of the national non-interventional study (NIS) HerSCin**

Author(s): Schmidt M, Kümmel S, Ruf-Dördelmann A, **Distelrath A**, Wacker J, Dietrich M, Schmatloch S, Lüdtke-Heckenkamp K